Toward a single-dose cure for buruli ulcer
A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a negle...
Saved in:
| Main Authors: | , , , , |
|---|---|
| 其他作者: | |
| 格式: | Article |
| 語言: | English |
| 出版: |
2021
|
| 主題: | |
| 在線閱讀: | https://hdl.handle.net/10356/148927 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|